ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0843

External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors
Abstract Number: 1710

Extl3 Involved in the Regulation of Endochondral Ossification in Axial SpA
Abstract Number: 1652

Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Abstract Number: 1023

Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors
Abstract Number: 0354

Factors Associated with Health Information Technology Use Among United States Adults with Arthritis from 2012-2017: Analysis of the National Health Interview Survey
Abstract Number: 2152

Factors Associated with Health-related Quality of Life in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – a Cross Sectional Analysis from the SAPHO-CNO Study
Abstract Number: 0420

Factors Associated with Infant Feeding Behaviors Among Women with Systemic Rheumatic Diseases
Abstract Number: 0366

Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Abstract Number: 0729

Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results
Abstract Number: 1106

Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Abstract Number: 0722

Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Abstract Number: 1441

Factors Associated with the Evolution of Degenerative Spinal Lesions in Axial Spondyloarthritis: 10-Year Follow-up of the DESIR Cohort
Abstract Number: 0538

Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study
Abstract Number: 2324

Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients with and Without First-degree Relatives with Psoriatic Disease
Abstract Number: 0436

Family Planning in Rheumatology: A Single Center Quality Improvement Project

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].